^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FREM1 (FRAS1 Related Extracellular Matrix 1)

    i
    Other names: FREM1, FRAS1 Related Extracellular Matrix 1, C9orf145, C9orf143, C9orf154, TILRR, FRAS1-Related Extracellular Matrix Protein 1, DKFZp686M16108, FLJ25461, Chromosome 9 Open Reading Frame 154, Extracellular Matrix Protein QBRICK, Protein QBRICK, TRIGNO2, BNAR, MOTA
    Associations

    News

    Trials
    3ms
    FREM1 serves as a novel therapeutic target in breast cancer through basement membrane-based prognostic modeling with integrated bioinformatics and experimental validation. (PubMed, Discov Oncol)
    Our study establishes BM-related genes as novel prognostic biomarkers and therapeutic targets in breast cancer. FREM1 in particular functions as a tumor suppressor by inhibiting cancer cell proliferation, migration, and invasion, highlighting its potential for therapeutic exploitation. These findings provide critical insights into BM-mediated tumor progression and suggest new avenues for targeted breast cancer therapy.
    Journal • IO biomarker
    |
    FREM1 (FRAS1 Related Extracellular Matrix 1)
    3ms
    Constructing an immune-related prognostic model and exploring the function of HMGB3, TNFSF4, and CORO2A in breast cancer. (PubMed, Transl Cancer Res)
    The Tumor Immune Dysfunctional and Exclusion (TIDE) scores were lower in the high-expression groups of HMGB3 and CORO2A, whereas the TIDE score was higher in the high-expression group of TNFSF4. This prognostic model reliably assessed risk for BC patients, providing critical guidance for precision oncology protocols and dynamic surveillance of disease progression.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • TNFSF4 (TNF Superfamily Member 4) • FREM1 (FRAS1 Related Extracellular Matrix 1) • SOCS3 (Suppressor Of Cytokine Signaling 3)
    10ms
    Identification of signature genes and subtypes for heart failure diagnosis based on machine learning. (PubMed, Front Cardiovasc Med)
    Our research identified four unique genes (FCN3, FREM1, MNS1, and SMOC2), enhancing our comprehension of the causes of HF. This provides new diagnostic insights and potentially establishes a tailored approach for individualized HF treatment.
    Journal
    |
    FREM1 (FRAS1 Related Extracellular Matrix 1)
    over2years
    Oncogenic miR-1825 promotes head and neck carcinogenesis via targeting FREM1. (PubMed, J Cell Biochem)
    We also identified FREM1 as a direct target of miR-1825 and demonstrated its reduced expression in HNSCC samples using immunohistochemistry analysis. Collectively, we suggest that the miR-1825/FREM1 axis serves as an important mediator of HNSCC development, where miR-1825 acts as an oncogene.
    Journal
    |
    MIR182 (MicroRNA 182) • FREM1 (FRAS1 Related Extracellular Matrix 1)
    over2years
    Establishment of a N1-methyladenosine-related risk signature for breast carcinoma by bioinformatics analysis and experimental validation. (PubMed, Breast Cancer)
    An mA RNA methylation regulator-related prognostic model was constructed, and a nomogram based on the prognostic model was constructed to provide a theoretical reference for individual counseling and clinical preventive intervention in BRCA.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • BRCA (Breast cancer early onset) • PD-L2 (Programmed Cell Death 1 Ligand 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • IDO1 (Indoleamine 2,3-dioxygenase 1) • ICOS (Inducible T Cell Costimulator) • CD27 (CD27 Molecule) • COL17A1 (Collagen Type XVII Alpha 1 Chain) • FREM1 (FRAS1 Related Extracellular Matrix 1) • MEOX1 (Mesenchyme Homeobox 1) • TNN (Tenascin N)